書籍情報から探す
Lessons Learned : Challenges in the Design of the First Pivotal Phase III Trials for a New Indication
Andrew J.Cole
MGH Epilepsy Service, Department of Neurology, Massachusetts General Hospital, Harvard Medical School
Neurological Therapeutics 36 (6) S99-S100, 2019.
MGH Epilepsy Service, Department of Neurology, Massachusetts General Hospital, Harvard Medical School
Neurological Therapeutics 36 (6) S99-S100, 2019.
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease
Ruey-Meei Wu
Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University
Neurological Therapeutics 36 (6) S101-S102, 2019.
Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University
Neurological Therapeutics 36 (6) S101-S102, 2019.
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
PET imaging of amyloid and tau[Machine Translation] (アミロイドとタウのPETイメージング)
古川勝敏
東北医科薬科大学医学部地域医療学教室・総合診療科
Neurological Therapeutics 36 (6) S112-S112, 2019.
東北医科薬科大学医学部地域医療学教室・総合診療科
Neurological Therapeutics 36 (6) S112-S112, 2019.
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
OD5-3. ヌシネルセン髄注投与に工夫を要した成人の脊髄性筋萎縮症3型の1例
OD5-5. 遅発型脊髄性筋萎縮症 (SMA) 患者に対するヌシネルセン長期治療評価 : SHINE試験中間解析
Darras BT1, Chiriboga CA2, Iannaccone ST3, Swoboda K4, Finkel R5, Tulinius M6, Saito K7, Montes J2, Mignon L8, Sun P9, Bhan I9, Gheuens S9, Reyna SP9, Farwell W9, De Vivo DC2, Matsuda N9
1Boston Children's Hospital and Harvard Medical School, 2Columbia University Irving Medical Center, 3University of Texas Southwestern Medical Center, 4Massachusetts General Hospital, 5Nemours Children's Hospital, 6University of Gothenburg, 7Tokyo Women's Hospital, 8Ionis Pharmaceuticals, 9Biogen
神経治療学 36 (6) S230-S230, 2019.
1Boston Children's Hospital and Harvard Medical School, 2Columbia University Irving Medical Center, 3University of Texas Southwestern Medical Center, 4Massachusetts General Hospital, 5Nemours Children's Hospital, 6University of Gothenburg, 7Tokyo Women's Hospital, 8Ionis Pharmaceuticals, 9Biogen
神経治療学 36 (6) S230-S230, 2019.
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
OD5-6. 遅発型脊髄性筋萎縮症 (SMA) 患者に対するヌシネルセン長期治療評価 : SHINE非盲検延長試験中間解析
Darras BT1, Farrar MA2, Mercuri E3, Chiriboga CA4, Kirschner J5, Kuntz N6, Shieh P7, Tulinius M8, Montes J9, Gambino G10, Foster R10, Bhan I10, Farwell W10, Reyna SP10, Matsuda N10
1Boston Children's Hospital, 2Sydney Children's Hospital, 3Universita Cattolica del Sacro Cuore, 4Columbia University Medical Center, 5Medical Center-University of Freiburg, 6Ann & Robert H. Lurie Children's Hospital of Chicago, 7University of California, 8The Queen Silvia Children's Hospital, 9Columbia University, 10Biogen
神経治療学 36 (6) S230-S230, 2019.
1Boston Children's Hospital, 2Sydney Children's Hospital, 3Universita Cattolica del Sacro Cuore, 4Columbia University Medical Center, 5Medical Center-University of Freiburg, 6Ann & Robert H. Lurie Children's Hospital of Chicago, 7University of California, 8The Queen Silvia Children's Hospital, 9Columbia University, 10Biogen
神経治療学 36 (6) S230-S230, 2019.
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
OD14-1. 抗AChR抗体陽性重症筋無力症におけるタクロリムス減量による再発危険因子の検討
PD4-4. フマル酸ジメチル投与下多発性硬化症患者における髄鞘再生の評価 - q-Space Myelin Map法の応用
PD4-6. 二次性進行型多発性硬化症患者におけるシポニモドの有効性と安全性 : 第III相国際共同治験 (EXPAND) の結果
上田兼吾1, Ludwig Kappos2, Robert Fox3, Amit Bar-Or4, Bruce Cree5, Gavin Giovannoni6, Ralf Gold7, Patrick Vermersch8, Sophie Arnould9, Harold Pohlmann9, Tatiana Sidorenko9, Christian Wolf10, Erik Wallstrom9, Frank Dahlke9
1ノバルティスファーマ株式会社, 2Neurology, University Hospital Basel, 3Cleveland Clinic, 4Montreal Neurological Institute, 5UCSF, Multiple Sclerosis Center, 6Royal London Hospital, 7Neurologische Universitaetsklinik, 8CHR de Lille, 9Novartis Pharma AG, 10Lycalis Sprl
神経治療学 36 (6) S272-S272, 2019.
1ノバルティスファーマ株式会社, 2Neurology, University Hospital Basel, 3Cleveland Clinic, 4Montreal Neurological Institute, 5UCSF, Multiple Sclerosis Center, 6Royal London Hospital, 7Neurologische Universitaetsklinik, 8CHR de Lille, 9Novartis Pharma AG, 10Lycalis Sprl
神経治療学 36 (6) S272-S272, 2019.
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
